OS07.2 Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the ARTE trial

BACKGROUND: Two phase III trials of bevacizumab (BEV) in newly diagnosed glioblastoma demonstrated prolonged progression-free survival (PFS), but failed to prolong overall survival (OS). Retrospective reports and early phase trials of bevacizumab in glioblastoma patients emphasized that benefit was...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Wirsching, H. G., Tabatabai, G., Hottinger, A., Plasswilm, L., Roelcke, U., Conen, K., Held, L., Rushing, E. J., Ochsenbein, A., Weller, M.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2017
Sujets:
ORAL PRESENTATIONS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5463629/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.043
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires